

Bibliography: Anemia

Berger A, Kallich J, Oster G. Use of darbepoetin alfa and epoetin alfa for anemia in clinical practice. Presented at the 18th Annual Symposium of the Multinational Association of Supportive Care in Cancer; June 22–24, 2006; Toronto, Canada. Abstract 02-007.

Canon J, Vansteenkiste J, Bodoky G, et al. Correction of chemotherapy-induced anemia and maintenance of hemoglobin levels using 500-mcg darbepoetin alfa every three weeks: analysis of dose reductions in a randomized, double-blind, active-controlled trial. Presented at the 17th International Congress on Anti-Cancer Treatment; January 30–February 2, 2006; Paris, France.

Cella D, Viswanathan H, Hays RD, et al. Development of the functional capacity screening tool (FCST): a brief instrument to identify functional capacity deficits in anemic cancer patients. Presented at the 42nd Annual Meeting of the American Society of Clinical Oncology; June 2–6, 2006; Atlanta, Georgia. Abstract 8593.

Chang J, Chan D, Camacho F. Early intervention with epoetin alfa is associated with reduced drug utilization in anemic breast cancer patients. Presented at the 29th Annual San Antonio Breast Cancer Symposium; December 14–17, 2006; San Antonio, Texas. Abstract 6080.

Chen E, Peake C, Buscaino E, Forlenza J, Bookhart B, McKenzie RS. Hematologic outcomes and erythropoiesis-stimulating therapy costs in epoetin alfa- and darbepoetin alfa-treated cancer patients: results of the Dosing and Outcomes Study of Erythropoiesis-stimulating therapies (DOSE) registry. Presented at the 48th Annual Meeting of the American Society of Hematology; December 9–12, 2006; Orlando, Florida. Abstract 3340.

Coleman EA, Coon SK, Kennedy R, Lockhart K, Anaissie EJ, Barlogie B. Benefits of exercise in combination with epoetin alfa for multiple myeloma. Presented at the 42nd Annual Meeting of the American Society of Clinical Oncology; June 2–6, 2006; Atlanta, Georgia. Abstract 8605.

Gabrilove J, Paquette R, Lyons R, et al. Darbepoetin alfa for treating anemia in patients with low-risk myelodysplastic syndromes: exploratory analysis of baseline predictors of response. Presented at the 42nd Annual Meeting of the American Society of Clinical Oncology; June 2–6, 2006; Atlanta, Georgia. Abstract 6579.

Gabrilove J, Paquette R, Lyons RM, et al. The efficacy and safety of darbepoetin alfa for treating anemia in low-risk myelodysplastic syndrome patients: results after 53/55 weeks. Presented at the 48th Annual Meeting of the American Society of Hematology; December 9–12, 2006; Orlando, Florida. Abstract 2671.

Gordon DH, Nichols G, Ben-Jacob A, et al. Treating anemia of cancer with darbepoetin alfa administered every 4 weeks: final results from a phase 2, randomized, double-blind, placebo-controlled study in cancer patients not receiving chemotherapy and/or radiotherapy. Presented at the 48th Annual Meeting of the American Society of Hematology; December 9–12, 2006; Orlando, Florida. Abstract 1304.

Henry DH, Kamin M, Wilhelm F, Williams D, Xie J, Woodman RC. Final results of a randomized study comparing two dosing regimens of epoetin alfa in patients with chemotherapy-induced anemia: 80,000 U every two weeks vs 40,000 U weekly. Presented at the 42nd Annual Meeting of the American Society of Clinical Oncology; June 2–6, 2006; Atlanta, Georgia. Abstract 8624.

Henry D, Viswanathan H, Wade SM, Servin M, Cella D. The patient's experience of fatigue: a cross-sectional study of cancer patients. Presented at the 48th Annual Meeting of the American Society of Hematology; December 9–12, 2006; Orlando, Florida. Abstract 3356.

Malik I, Kahanic S, Liu R, et al. Effectiveness of darbepoetin alfa administered every 3 weeks on clinical outcomes in patients with gastrointestinal cancer and chemotherapy-induced anemia. Presented at the American Society of Clinical Oncology Gastrointestinal Symposium; January 26–28, 2006; San Francisco, California. Abstract 382.

Mundle S, Lefebvre P, Duh MS, et al. Erythroid response (ER) rates in myelodysplastic syndromes (MDS) patients treated with epoetin alfa (EPO) or darbepoetin alfa (DARB) using International Working Group response criteria (IWGc): comparative meta-analysis. Presented at the 48th Annual Meeting of the American Society of Hematology; December 9–12, 2006; Orlando, Florida. Abstract 2672.

Paquette R, Gabrielove J, Lyons R, et al. Darbepoetin alfa for treating anemia in low-risk myelodysplastic syndrome patients: interim results after 27/28 weeks. Presented at the 42nd Annual Meeting of the American Society of Clinical Oncology; June 2–6, 2006; Atlanta, Georgia. Abstract 6564.

Ross SD, Allen IE, Henry D, Seaman C, Sercus B, Goodnough LT. Clinical benefits and risks associated with epoetin (alfa/beta) and darbepoetin alfa in patients with chemotherapy-induced anemia: a systematic review of the literature. Presented at the 18th Annual Symposium of the Multinational Association of Supportive Care in Cancer; June 22–24, 2006; Toronto, Canada. Abstract 02-006.

Schwartzberg L, Rearden T, Yee L, et al. A phase II, randomized, open-label study to assess the efficacy of extended-dose schedule administration of darbepoetin alfa in cancer patients with chemotherapy-induced anemia. Presented at the 48th Annual Meeting of the American Society of Hematology; December 9–12, 2006; Orlando, Florida. Abstract 1306.

Vandebroek A, Gaed B, Altintas S, et al. A randomized open-label study of darbepoetin alfa administered every 3 weeks with or without parenteral iron in anemic subjects with non-myeloid malignancies receiving chemotherapy. Presented at the 42nd Annual Meeting of the American Society of Clinical Oncology; June 2–6, 2006; Atlanta, Georgia. Abstract 8612.